Information Provided By: 
Fly News Breaks for July 27, 2016
AGN
Jul 27, 2016 | 08:18 EDT
Leerink analyst Jason Gerberry raised his price target for Allergan to $294 from $272 to reflect his increased confidence in the company's new product pipeline to deliver about $4.6B in revenue by 2021. The analyst is encouraged the target can be met largely from clinically de-risked assets, leaving substantial upside if Allergan's more speculative programs deliver. Leerink has an Outperform rating on the shares.
News For AGN From the Last 2 Days
There are no results for your query AGN
